TapewireFind a company

person · Reporting owner

Cowie Robin Harper

Disclosed activity across 1 company

Tapewire entity
65171
SEC CIK
0001827690

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
BIODESIX INCBDSX · Entity 6053CFO, Sec'y & TreasurerFebruary 20, 2026February 24, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BIODESIX INC

Report date February 20, 2026 · Filed February 24, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect16,231 Ending reported balance After 2026-02-23 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-02-20 · Exercise / conversion · Acquired 1,469 · Balance 16,766

F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

Row 2 · 2026-02-23 · Sale · Disposed 535 · Balance 16,231

F2: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

F3: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $12.58 to $13.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect4,406 Reported balance After 2026-02-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-02-20 · Exercise / conversion · Disposed 1,469 · Balance 4,406

F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F4: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025.

F5: These RSUs vest in a series of four successive equal annual installments measured from February 20, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F2: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

F3: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $12.58 to $13.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025.

F5: These RSUs vest in a series of four successive equal annual installments measured from February 20, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
February 08, 2024 Filed Feb 13, 2024 02:44 UTC BIODESIX INC BDSX · Entity 6053 GrantStock Options (Right to buy) · Derivative 128,761 $0.00 Strike: $1.99 $0.00
Disclosure

SEC source: 0000905148-24-000583 · form4.xml · derivative · entry 5

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 128,761

Underlying: Common Stock · 128,761 shares

Expires 2034-02-07

F6 · derivative.exercise_date: This option vests in a series of forty-eight successive equal monthly installments measured from January 15, 2024, generally subject to the Reporting Person's continuous service through each applicable vesting date.

Read SEC document
February 08, 2024 Filed Feb 13, 2024 02:44 UTC BIODESIX INC BDSX · Entity 6053 GrantRestricted Stock Units · Derivative 64,381 $0.00 $0.00
Disclosure

SEC source: 0000905148-24-000583 · form4.xml · derivative · entry 4

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,381

Underlying: Common Stock · 64,381 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F5 · derivative.exercise_date: These RSUs vest in a series of four successive equal annual installments measured from January 15, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F5 · derivative.expiration_date: These RSUs vest in a series of four successive equal annual installments measured from January 15, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Read SEC document
February 08, 2024 Filed Feb 13, 2024 02:44 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionCommon Stock 51,692 Not disclosed Not disclosed
Disclosure

SEC source: 0000905148-24-000583 · form4.xml · nonDerivative · entry 1

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 188,265

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
November 10, 2023 Filed Nov 13, 2023 21:50 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 491 $1.23 $601.77
Disclosure

SEC source: 0000905148-23-001381 · form4.xml · nonDerivative · entry 3

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 136,573

F3 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

F5 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.19 to $1.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
November 09, 2023 Filed Nov 13, 2023 21:50 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 491 $1.27 $623.91
Disclosure

SEC source: 0000905148-23-001381 · form4.xml · nonDerivative · entry 2

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 137,064

F3 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

F4 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.23 to $1.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 21:50 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 3,156 $0.00 $0.00
Disclosure

SEC source: 0000905148-23-001381 · form4.xml · derivative · entry 4

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,411

Underlying: Common Stock · 3,156 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F6 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F6 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 21:50 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionCommon Stock 3,156 Not disclosed Not disclosed
Disclosure

SEC source: 0000905148-23-001381 · form4.xml · nonDerivative · entry 1

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 137,555

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F2 · balance_after: Includes 2,864 shares purchased under the Issuer's Employee Stock Purchase Plan on August 31, 2023.

Read SEC document
August 10, 2023 Filed Aug 10, 2023 23:27 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 1,788 $1.27 $2,265.22
Disclosure

SEC source: 0000905148-23-000664 · form4.xml · nonDerivative · entry 3

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 131,535

F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

F4 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.21 to $1.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
August 09, 2023 Filed Aug 10, 2023 23:27 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 1,789 $1.39 $2,483.67
Disclosure

SEC source: 0000905148-23-000664 · form4.xml · nonDerivative · entry 2

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 133,323

F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

F3 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.21 to $1.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
August 08, 2023 Filed Aug 10, 2023 23:27 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 8,418 $0.00 $0.00
Disclosure

SEC source: 0000905148-23-000664 · form4.xml · derivative · entry 5

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,418 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F6 · derivative.exercise_date: These RSUs vest in a series of six successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F6 · derivative.expiration_date: These RSUs vest in a series of six successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Read SEC document
August 08, 2023 Filed Aug 10, 2023 23:27 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 3,157 $0.00 $0.00
Disclosure

SEC source: 0000905148-23-000664 · form4.xml · derivative · entry 4

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,567

Underlying: Common Stock · 3,157 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F5 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F5 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Read SEC document
August 08, 2023 Filed Aug 10, 2023 23:27 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionCommon Stock 11,575 Not disclosed Not disclosed
Disclosure

SEC source: 0000905148-23-000664 · form4.xml · nonDerivative · entry 1

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 135,112

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
August 03, 2023 Filed Aug 7, 2023 21:28 UTC BIODESIX INC BDSX · Entity 6053 GrantCommon Stock 6,172 $1.62 $9,998.64
Disclosure

SEC source: 0000905148-23-000620 · form4.xml · nonDerivative · entry 1

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 123,537

Read SEC document
July 24, 2023 Filed Jul 26, 2023 22:13 UTC BIODESIX INC BDSX · Entity 6053 GrantStock Options (Right to buy) · Derivative 27,138 Not disclosed Strike: $1.20 Not disclosed
Disclosure

SEC source: 0000905148-23-000510 · form4.xml · derivative · entry 5

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,138

Underlying: Common Stock · 27,138 shares

Expires 2033-07-23

F3 · kind: On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than $10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023.

F4 · kind: The Reporting Person elected to participate in the Tender Offer and received 27,138 Replacement Options with an exercise price of $1.20 per share in exchange for 132,963 Surrendered Options with an exercise price of $20.67 per share, after which the Surrendered Options were cancelled.

F3 · price: On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than $10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023.

F4 · price: The Reporting Person elected to participate in the Tender Offer and received 27,138 Replacement Options with an exercise price of $1.20 per share in exchange for 132,963 Surrendered Options with an exercise price of $20.67 per share, after which the Surrendered Options were cancelled.

F5 · derivative.exercise_date: This Replacement Option vests as follows: 20,659 shares of Common Stock underlying this Replacement Option vest on August 1, 2024, and the remaining 6,479 shares of Common Stock underlying this Replacement Option vest in 31 successive, equal monthly installments beginning on August 1, 2024.

Read SEC document
July 24, 2023 Filed Jul 26, 2023 22:13 UTC BIODESIX INC BDSX · Entity 6053 Disposition to issuerStock Options (Right to buy) · Derivative 71,524 Not disclosed Strike: $20.67 Not disclosed
Disclosure

SEC source: 0000905148-23-000510 · form4.xml · derivative · entry 4

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 71,524 shares

Expires 2031-02-22

F3 · kind: On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than $10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023.

F4 · kind: The Reporting Person elected to participate in the Tender Offer and received 27,138 Replacement Options with an exercise price of $1.20 per share in exchange for 132,963 Surrendered Options with an exercise price of $20.67 per share, after which the Surrendered Options were cancelled.

F3 · price: On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than $10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023.

F4 · price: The Reporting Person elected to participate in the Tender Offer and received 27,138 Replacement Options with an exercise price of $1.20 per share in exchange for 132,963 Surrendered Options with an exercise price of $20.67 per share, after which the Surrendered Options were cancelled.

F2 · derivative.exercise_date: This option was fully vested as of the grant date.

Read SEC document
July 24, 2023 Filed Jul 26, 2023 22:13 UTC BIODESIX INC BDSX · Entity 6053 Disposition to issuerStock Options (Right to buy) · Derivative 61,439 Not disclosed Strike: $20.67 Not disclosed
Disclosure

SEC source: 0000905148-23-000510 · form4.xml · derivative · entry 3

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 61,439 shares

Expires 2031-02-22

F3 · kind: On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than $10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023.

F4 · kind: The Reporting Person elected to participate in the Tender Offer and received 27,138 Replacement Options with an exercise price of $1.20 per share in exchange for 132,963 Surrendered Options with an exercise price of $20.67 per share, after which the Surrendered Options were cancelled.

F3 · price: On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than $10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023.

F4 · price: The Reporting Person elected to participate in the Tender Offer and received 27,138 Replacement Options with an exercise price of $1.20 per share in exchange for 132,963 Surrendered Options with an exercise price of $20.67 per share, after which the Surrendered Options were cancelled.

F1 · derivative.exercise_date: This option was scheduled to vest in a series of 60 successive, equal monthly installments measured from February 23, 2021.

Read SEC document
May 10, 2023 Filed May 11, 2023 00:16 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 973 $1.58 $1,533.55
Disclosure

SEC source: 0001140361-23-023969 · form4.xml · nonDerivative · entry 3

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 117,365

F3 · kind: These shares of the Issuer's common stock were sold automatically to cover taxes upon the vesting of RSUs.

F5 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.5332 to $1.615, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
May 09, 2023 Filed May 11, 2023 00:16 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 2,512 $1.57 $3,934.80
Disclosure

SEC source: 0001140361-23-023969 · form4.xml · nonDerivative · entry 2

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 118,338

F3 · kind: These shares of the Issuer's common stock were sold automatically to cover taxes upon the vesting of RSUs.

F4 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.53 to $1.6039, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
May 08, 2023 Filed May 11, 2023 00:16 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 8,418 $0.00 $0.00
Disclosure

SEC source: 0001140361-23-023969 · form4.xml · derivative · entry 5

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,418

Underlying: Common Stock · 8,418 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock.

F7 · derivative.exercise_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F7 · derivative.expiration_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Read SEC document
May 08, 2023 Filed May 11, 2023 00:16 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 3,157 $0.00 $0.00
Disclosure

SEC source: 0001140361-23-023969 · form4.xml · derivative · entry 4

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,724

Underlying: Common Stock · 3,157 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock.

F6 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F6 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Read SEC document
May 08, 2023 Filed May 11, 2023 00:16 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionCommon Stock 11,575 Not disclosed Not disclosed
Disclosure

SEC source: 0001140361-23-023969 · form4.xml · nonDerivative · entry 1

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,850

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock.

F2 · balance_after: Includes 10,000 shares purchased under the Issuer's Employee Stock Purchase Plan on February 28, 2023.

Read SEC document
March 01, 2023 Filed Mar 3, 2023 21:16 UTC BIODESIX INC BDSX · Entity 6053 GrantStock Options (Right to buy) · Derivative 148,448 $0.00 Strike: $2.00 $0.00
Disclosure

SEC source: 0001140361-23-010025 · form4.xml · derivative · entry 1

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 148,448

Underlying: Common Stock · 148,448 shares

Expires 2033-02-28

F1 · derivative.exercise_date: This option vested in full on March 1, 2023. Under the Issuer's 2022 Bonus-to-Options Program, the Reporting Person elected to receive a portion of the annual cash bonus earned during 2022 in the form of a fully-vested option.

Read SEC document
February 09, 2023 Filed Feb 10, 2023 23:40 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 4,220 $1.80 $7,592.20
Disclosure

SEC source: 0001140361-23-006074 · form4.xml · nonDerivative · entry 2

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,275

F2 · kind: These shares of Issuer's common stock were sold automatically to cover taxes upon the vesting of RSUs.

F3 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.71 to $1.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
February 08, 2023 Filed Feb 10, 2023 23:40 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 8,418 $0.00 $0.00
Disclosure

SEC source: 0001140361-23-006074 · form4.xml · derivative · entry 5

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,836

Underlying: Common Stock · 8,418 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of Issuer's common stock.

F6 · derivative.exercise_date: These RSUs vest in a series of six successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F6 · derivative.expiration_date: These RSUs vest in a series of six successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Read SEC document
February 08, 2023 Filed Feb 10, 2023 23:40 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 3,157 $0.00 $0.00
Disclosure

SEC source: 0001140361-23-006074 · form4.xml · derivative · entry 4

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,881

Underlying: Common Stock · 3,157 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of Issuer's common stock.

F5 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F5 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Read SEC document
February 08, 2023 Filed Feb 10, 2023 23:40 UTC BIODESIX INC BDSX · Entity 6053 GrantRestricted Stock Units · Derivative 194,141 $0.00 $0.00
Disclosure

SEC source: 0001140361-23-006074 · form4.xml · derivative · entry 3

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 194,141

Underlying: Common Stock · 194,141 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of Issuer's common stock.

F4 · derivative.exercise_date: These RSUs vest in a series of four successive equal annual installments measured from February 8, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F4 · derivative.expiration_date: These RSUs vest in a series of four successive equal annual installments measured from February 8, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Read SEC document
February 08, 2023 Filed Feb 10, 2023 23:40 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionCommon Stock 11,575 Not disclosed Not disclosed
Disclosure

SEC source: 0001140361-23-006074 · form4.xml · nonDerivative · entry 1

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 103,495

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of Issuer's common stock.

Read SEC document
November 21, 2022 Filed Nov 21, 2022 23:02 UTC BIODESIX INC BDSX · Entity 6053 GrantCommon Stock 17,391 $1.15 $19,999.65
Disclosure

SEC source: 0001140361-22-042594 · form4.xml · nonDerivative · entry 1

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,920

Read SEC document
November 10, 2022 Filed Nov 11, 2022 02:02 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 1,583 $1.02 $1,610.70
Disclosure

SEC source: 0001140361-22-041079 · form4.xml · nonDerivative · entry 3

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,529

F4 · kind: These Shares were sold automatically to cover taxes upon the vesting of RSUs.

F6 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.00 to $1.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
November 09, 2022 Filed Nov 11, 2022 02:02 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 1,999 $1.04 $2,082.56
Disclosure

SEC source: 0001140361-22-041079 · form4.xml · nonDerivative · entry 2

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,112

F4 · kind: These Shares were sold automatically to cover taxes upon the vesting of RSUs.

F5 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.00 to $1.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
November 08, 2022 Filed Nov 11, 2022 02:02 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 8,418 $0.00 $0.00
Disclosure

SEC source: 0001140361-22-041079 · form4.xml · derivative · entry 5

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,254

Underlying: Common Stock · 8,418 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share").

F3 · derivative.exercise_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

F3 · derivative.expiration_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

Read SEC document
November 08, 2022 Filed Nov 11, 2022 02:02 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 3,156 $0.00 $0.00
Disclosure

SEC source: 0001140361-22-041079 · form4.xml · derivative · entry 4

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,038

Underlying: Common Stock · 3,156 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share").

F2 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

F2 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

Read SEC document
November 08, 2022 Filed Nov 11, 2022 02:02 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionCommon Stock 11,574 Not disclosed Not disclosed
Disclosure

SEC source: 0001140361-22-041079 · form4.xml · nonDerivative · entry 1

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,111

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share").

Read SEC document
August 09, 2022 Filed Aug 10, 2022 22:53 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 3,533 $2.53 $8,932.13
Disclosure

SEC source: 0001140361-22-029137 · form4.xml · nonDerivative · entry 2

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,537

F4 · kind: These Shares were sold automatically to cover taxes upon the vesting of RSUs.

F5 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $2.38 to $2.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
August 08, 2022 Filed Aug 10, 2022 22:53 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 8,418 $0.00 $0.00
Disclosure

SEC source: 0001140361-22-029137 · form4.xml · derivative · entry 4

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,672

Underlying: Common Stock · 8,418 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share").

F3 · derivative.exercise_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

F3 · derivative.expiration_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

Read SEC document
August 08, 2022 Filed Aug 10, 2022 22:53 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 3,157 $0.00 $0.00
Disclosure

SEC source: 0001140361-22-029137 · form4.xml · derivative · entry 3

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,194

Underlying: Common Stock · 3,157 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share").

F2 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

F2 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

Read SEC document
August 08, 2022 Filed Aug 10, 2022 22:53 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionCommon Stock 11,575 Not disclosed Not disclosed
Disclosure

SEC source: 0001140361-22-029137 · form4.xml · nonDerivative · entry 1

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,070

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share").

Read SEC document
May 10, 2022 Filed May 12, 2022 01:41 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 3,338 $1.83 $6,108.54
Disclosure

SEC source: 0001140361-22-018731 · form4.xml · nonDerivative · entry 2

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,495

F4 · kind: These Shares were sold automatically to cover taxes upon the vesting of RSUs.

F5 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.73 to $1.945, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
May 09, 2022 Filed May 12, 2022 01:41 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 8,418 $0.00 $0.00
Disclosure

SEC source: 0001140361-22-018731 · form4.xml · derivative · entry 4

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,090

Underlying: Common Stock · 8,418 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share").

F3 · derivative.exercise_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

F3 · derivative.expiration_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

Read SEC document
May 09, 2022 Filed May 12, 2022 01:41 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 3,157 $0.00 $0.00
Disclosure

SEC source: 0001140361-22-018731 · form4.xml · derivative · entry 3

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,351

Underlying: Common Stock · 3,157 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share").

F2 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

F2 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

Read SEC document
May 09, 2022 Filed May 12, 2022 01:41 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionCommon Stock 11,575 Not disclosed Not disclosed
Disclosure

SEC source: 0001140361-22-018731 · form4.xml · nonDerivative · entry 1

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,833

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share").

F6 · balance_after: Includes 2,604 Shares acquired under the BDSX stock purchase plan on February 28, 2022.

Read SEC document
March 10, 2022 Filed Mar 14, 2022 21:39 UTC BIODESIX INC BDSX · Entity 6053 GrantStock Options (Right to buy) · Derivative 27,758 $0.00 Strike: $2.29 $0.00
Disclosure

SEC source: 0001567619-22-006911 · doc1.xml · derivative · entry 3

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,758

Underlying: Common Stock · 27,758 shares

Expires 2032-03-09

Read SEC document
March 10, 2022 Filed Mar 14, 2022 21:39 UTC BIODESIX INC BDSX · Entity 6053 GrantStock Options (Right to buy) · Derivative 5,896 $0.00 Strike: $0.77 $0.00
Disclosure

SEC source: 0001567619-22-006911 · doc1.xml · derivative · entry 2

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,792

Underlying: Common Stock · 5,896 shares

Expires 2029-03-21

F1 · shares: On March 22, 2019, the Reporting Person was granted an option to purchase 17,688 shares (as-adjusted for the 0.1684664-for-1 reverse stock split effected on October 19, 2020), the vesting of which was subject to the Issuer's satisfaction of certain performance criteria for each of the 2019, 2020 and 2021 fiscal years. The performance criteria was not met for fiscal year 2019, resulting in the cancellation of 5,896 shares underlying the option.

F3 · shares: On March 10, 2022, the Compensation Committee confirmed the performance criteria were met for fiscal year 2021, resulting in the vesting of 5,896 shares underlying the option.

F1 · derivative.exercise_date: On March 22, 2019, the Reporting Person was granted an option to purchase 17,688 shares (as-adjusted for the 0.1684664-for-1 reverse stock split effected on October 19, 2020), the vesting of which was subject to the Issuer's satisfaction of certain performance criteria for each of the 2019, 2020 and 2021 fiscal years. The performance criteria was not met for fiscal year 2019, resulting in the cancellation of 5,896 shares underlying the option.

F3 · derivative.exercise_date: On March 10, 2022, the Compensation Committee confirmed the performance criteria were met for fiscal year 2021, resulting in the vesting of 5,896 shares underlying the option.

Read SEC document
February 08, 2022 Filed Feb 11, 2022 00:09 UTC BIODESIX INC BDSX · Entity 6053 GrantRestricted Stock Units · Derivative 50,508 $0.00 $0.00
Disclosure

SEC source: 0001140361-22-004589 · form4.xml · derivative · entry 2

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,508

Underlying: Common Stock · 50,508 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock.

F3 · derivative.exercise_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

F3 · derivative.expiration_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

Read SEC document
February 08, 2022 Filed Feb 11, 2022 00:09 UTC BIODESIX INC BDSX · Entity 6053 GrantRestricted Stock Units · Derivative 50,508 $0.00 $0.00
Disclosure

SEC source: 0001140361-22-004589 · form4.xml · derivative · entry 1

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,508

Underlying: Common Stock · 50,508 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock.

F2 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

F2 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

Read SEC document
January 13, 2022 Filed Jan 18, 2022 22:38 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionStock Options (Right to buy) · Derivative 3,159 $0.00 Strike: $0.42 $0.00
Disclosure

SEC source: 0001567619-22-001264 · doc1.xml · derivative · entry 4

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,210

Underlying: Common Stock · 3,159 shares

Expires 2028-04-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option vests in 60 successive, equal monthly installments measured from January 1, 2018.

Read SEC document
January 13, 2022 Filed Jan 18, 2022 22:38 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionStock Options (Right to buy) · Derivative 2,520 $0.00 Strike: $0.42 $0.00
Disclosure

SEC source: 0001567619-22-001264 · doc1.xml · derivative · entry 3

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,520 shares

Expires 2027-05-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option vested in 60 successive, equal monthly installments measured from January 1, 2017.

Read SEC document
January 13, 2022 Filed Jan 18, 2022 22:38 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionCommon Stock 3,159 $0.42 $1,326.78
Disclosure

SEC source: 0001567619-22-001264 · doc1.xml · nonDerivative · entry 2

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,654

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 13, 2022 Filed Jan 18, 2022 22:38 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionCommon Stock 2,520 $0.42 $1,058.40
Disclosure

SEC source: 0001567619-22-001264 · doc1.xml · nonDerivative · entry 1

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,495

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 17, 2021 Filed Nov 18, 2021 22:42 UTC BIODESIX INC BDSX · Entity 6053 PurchaseCommon Stock 1,000 $6.51 $6,510.00
Disclosure

SEC source: 0001567619-21-020775 · doc1.xml · nonDerivative · entry 1

Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,975

F1 · price: The price reported in Column 4 is a weighted average price. These shares of Common Stock were purchased in multiple transactions at prices ranging from $6.41 to $6.61, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F2 · balance_after: Includes 1,262 shares acquired under the BDSX stock purchase plan on August 31, 2021.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.